EBITDA (Annual)

EBITDA: Income before interest, taxes, depreciation and amortization.

Pacira BioSciences, Inc. (PCRX) had EBITDA of $108.28M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$726.41M
Net Income	$7.03M
Cost of Goods Sold	$149.75M
Gross Profit	$576.66M
Operating Expenses	$707.22M
Operating Income	$19.19M
Non-Operating Income/Expense	$-2.32M
Pre-Tax Income	$16.87M
Normalized Pre-Tax Income	$16.87M
Income after Taxes	$7.03M
Income from Continuous Operations	$7.03M
Consolidated Net Income/Loss	$7.03M
Normalized Income after Taxes	$7.03M
EBIT	$19.19M
EBITDA	$108.28M
Weighted-Average Shares Outstanding (Basic)	44.57M
Weighted-Average Shares Outstanding (Diluted)	45.04M
Earnings per Share (EPS) (Basic)	$0.16
Earnings per Share (EPS) (Diluted)	$0.16
Balance Sheet Financials
Current Assets	$547.97M
Property, Plant, and Equipment	$140.69M
Long-Term Assets	$716.94M
Total Assets	$1.26B
Current Liabilities	$120.59M
Long-Term Debt	$372.19M
Long-Term Liabilities	$451.22M
Total Liabilities	$571.81M
Common Equity	$693.11M
Tangible Shareholders Equity	$304.80M
Shareholders Equity	$693.11M
Common Shares Outstanding	41.12M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$151.99M
Cash Flow from Investing Activities	$99.48M
Cash Flow from Financial Activities	$-369.63M
Beginning Cash	$276.77M
End Cash	$158.54M
Increase/Decrease in Cash	$-118.23M
Stock-Based Compensation	$57.50M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.54
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.35
Debt to Equity Ratio	0.54
Gross Margin	79.39%
Operating Margin	2.64%
EBIT Margin	2.64%
EBITDA Margin	14.91%
Pre-Tax Profit Margin	2.32%
Profit Margin	0.97%
Free Cash Flow	$136.66M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.57
Inventory Turnover	0.98
Receiveable Turnover	5.85
Days Sales in Receivables	62.34
Return on Equity	1.01%
Return on Tangible Equity	2.31%
Return on Assets	0.56%
Return on Investments	0.66%
Book Value Per Share	$16.86
Free Cash Flow per Share	$3.03
Operating Cash Flow per Share	$3.37

Data from Zacks Investment Research, Inc.